Overview

A Safety and Efficacy Study for Combinational Treatment of DaRT and Check Point Inhibitor for Recurrent Unresectable or mHNSCC

Status:
Recruiting

Trial end date:
2026-06-01

Target enrollment:

Participant gender:

Summary

A unique combinational treatment for cancer employing intratumoral diffusing alpha radiation emitter device with check point inhibitor for recurrent unresectable or metastatic Head and Neck Squamous Cell Carcinoma

Phase:

N/A

Details

Lead Sponsor:

Alpha Tau Medical LTD.

Treatments:

Pembrolizumab